Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) — The “AI in Pharma Global Market Opportunities and Strategies to 2032” report has been added to ResearchAndMarkets.com’s offering.
New research highlighting transformative opportunities within the global AI in pharma market has been added to our comprehensive collection of industry analysis, with a focus on projected growth through to the year 2032. This newly published report dissects key segments where AI is impacting pharmaceuticals, ranging from drug discovery to the implementation of cloud-based services.
Global Market Growth In a remarkable show of progress, the AI in pharma market value surged to nearly $1.47 billion in 2022 and is expected to expand at a CAGR of 33.6% to reach $6.29 billion by 2027. With sustained momentum, the market is further projected to grow at a CAGR of 18.9% leading up to $14.95 billion in 2032.
Segmentation Insights
- Analyzing by technology, deep learning dominated the market in 2022, representing a substantial portion of the industry’s earnings, whereas context-aware processing is anticipated to exhibit the fastest growth through to 2027.
- In terms of drug type, small molecules contributed to over half of the market’s total value, yet large molecules are predicted to accelerate rapidly in the forthcoming years.
- Within the application-based analysis, drug discovery leads the AI utilization in pharma, and is expected to continue this trend, with clinical trial research poised for a steep upward trajectory.
Regional Overview Dynamic Growth Across Continents
North America currently stands as the leading region in the AI in pharma market, closely followed by Western Europe and Asia Pacific. However, regions such as South America and Asia Pacific are anticipated to become the fastest-growing regions, with Eastern Europe and Africa also gearing up for significant expansion.
Competitive Landscape
The market landscape presents a mix of large-scale and smaller competitors, with the current market being moderately fragmented. Strategic acquisitions, partnerships, and collaborations are instrumental as companies further their innovations and consolidate their positions worldwide.
Opportunistic Strategies for Market Players
Foresighted strategies are imperative for companies vying for leadership within the AI in pharma domain. The report recommends particular focus on the integration of generative AI, advancements in AI tools, and an emphasis on strategic partnerships to catalyze growth and investment opportunities.
Maximizing Emerging Potential
For an industry on the cusp of exponential growth, the report underscores the lucrative prospects in fast-developing technologies and growing applications. As players navigate this landscape, there is an encouragement to leverage opportunities in burgeoning markets, fine-tune pricing strategies, and bolster business visibility through industry events. This in-depth analysis offers a lens into the future of pharmaceuticals intertwined with AI technology, presenting data-driven insights for stakeholders looking to carve a substantial presence in an increasingly AI-influenced pharma industry.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 259 |
| Forecast Period | 2021 – 2031 |
| Estimated Market Value (USD) in 2021 | $1.47 Billion |
| Forecasted Market Value (USD) by 2031 | $14.95 Billion |
| Compound Annual Growth Rate | 26.0% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes
- Concerto Health AI
- Alphabet Inc
- OWKIN
- Nvidia Corporation
- Path AI
- Insilico Medicine
- Exscientia
- Microsoft Corporation
- XtalPi
- Intel
- Shanghai Pharmaceuticals
- China National Pharmaceutical Group Co., Ltd. (Sinopharm)
- Jiangsu Hengrui Medicine Co., Ltd
- Dr. Reddy’s Laboratories Ltd
- Sun Pharma
- Standigm
- Takeda Pharmaceutical Company Ltd
- Otsuka Pharmaceutical Co. Ltd
- Cipla Limited
- Aurobindo Pharma Limited
- Roche India
- Alliance Pharm Pte Ltd
- GSK Australia
- DeepMind
- GlaxoSmithKline
- Sanofi
- Bayer
- Renalytix AI
- Merck
- AstraZeneca
- Exscientia
- Iktos
- BenevolentAI
- Novartis
- Gero
- Ardigen
- Botkin
- Webiomed
- Care Mentor AI
- Diagnocat
- IBM Corporation
- Atomwise, Inc
- Cloud Pharmaceutical
- Bioage
- NuMedii
- Envisagenics
- Aria Pharmaceuticals
- Verge Genomics
- Berg LLC
- Deep Genomics
- Cyclica
- IQVIA
- Roche
- Novartis
- Pfizer
- PRA Healthscience
- Gesto
- Intensicare
- Epitrack
- GE Healthcare
- Welltok Inc
- Oncora Medical
- Recursion Pharmaceuticals Inc
- Nucleai
- Pepticom
- Rology
- hearX Group
- DilenyTech
- iNNOHEALTH Technology Solutions
For more information about this report visit https://www.researchandmarkets.com/r/ujefjq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global AI In Pharma Market
